ID: ALA345998

Max Phase: Preclinical

Molecular Formula: C22H18N2O6

Molecular Weight: 406.39

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCC1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc4c(cc3nc2-1)OCO4

Standard InChI:  InChI=1S/C22H18N2O6/c1-2-22(27)7-19(25)28-9-13-14(22)5-16-20-12(8-24(16)21(13)26)3-11-4-17-18(30-10-29-17)6-15(11)23-20/h3-6,27H,2,7-10H2,1H3

Standard InChI Key:  MWDHYRWFFNTLOV-UHFFFAOYSA-N

Associated Targets(Human)

DNA topoisomerase I 7553 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A-427 643 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

PC-3 62116 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

K562 73714 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

MCF7 126967 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 406.39Molecular Weight (Monoisotopic): 406.1165AlogP: 2.20#Rotatable Bonds: 1
Polar Surface Area: 99.88Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.81CX Basic pKa: 3.44CX LogP: 0.78CX LogD: 0.78
Aromatic Rings: 3Heavy Atoms: 30QED Weighted: 0.48Np Likeness Score: 0.88

References

1. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC..  (1998)  Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.,  41  (27): [PMID:9876111] [10.1021/jm980400l]
2. Huang Q, Wang L, Lu W..  (2013)  Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.,  63  [PMID:23578545] [10.1016/j.ejmech.2013.01.058]

Source